Romano A, Sadan Y
Maurice and Gabriela Goldschleger Eye Institute, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
Metab Pediatr Syst Ophthalmol (1985). 1988;11(1-2):43-6.
This review of ten years of experience presents the results of clinical use of human beta-interferon (Frone) in viral ocular disease. Two forms of human beta-interferon have been used: (a) Frone cream 20,000 IU/g (Inter-Yeda Ltd.) for local treatment and prevention of HSV-1 periocular skin lesions and for Herpes zoster ophthalmicus. (b) Frone eye drops (500,000-1,000,000 U) for prophylaxis and treatment of adenovirus infections and for prevention of recurrent HSV-1 keratitis. Our results show that Frone cream or drops, applied at an early stage, is: (a) Effective in significantly shortening the course of the disease; (b) Has a drying effect on herpetic skin lesions, and tear secretion in adeno viral disease; (c) Reduces the frequency from 1.2 to 0.04 attacks per year for patients with known biological rhythm of the disease; (d) Prevents subepithelial keratitis in 45% of the study population; (e) Prophylactic treatment of interferon in families reduces the incidence of contamination from 65% to 20%.
这篇关于十年经验的综述介绍了人β-干扰素(弗罗内)在病毒性眼病临床应用的结果。已使用两种形式的人β-干扰素:(a)20000 IU/g的弗罗内乳膏(以色列Yeda公司),用于局部治疗和预防单纯疱疹病毒1型(HSV-1)眼周皮肤病变以及眼部带状疱疹。(b)弗罗内滴眼液(500000 - 1000000 U),用于预防和治疗腺病毒感染以及预防复发性HSV-1角膜炎。我们的结果表明,早期应用弗罗内乳膏或滴眼液:(a)能有效显著缩短病程;(b)对疱疹性皮肤病变以及腺病毒疾病中的泪液分泌有干燥作用;(c)对于已知疾病生物节律的患者,将每年发作频率从1.2次降低至0.04次;(d)在45%的研究人群中预防了上皮下角膜炎;(e)在家庭中进行干扰素预防性治疗可将感染发生率从65%降低至20%。